Jubilant Of India Cleared For Takeover Of Canada’s Draxis
This article was originally published in PharmAsia News
India's Jubilant Organosys received clearance from shareholders of Draxis Health to acquire the Canadian biotech. Draxis said 99 percent of the shareholders approved the deal, but the merger must still be approved by the Quebec Superior Court. The move would give Jubilant entry into the North American market for radiopharmaceuticals. (Click here for more
You may also be interested in...
Lawyer asks US FDA to require another trial before licensing Mesoblast’s stem cell therapy for children with SR-aGVHD; Incyte’s Jakafi is only product approved for the indication.
Hanmi licenses out GLP-1/glucagon receptor dual agonist for NASH to Merck, in a deal worth up to $870m, marking a positive turn for the Korean firm's pipeline after Janssen returned rights last year.
Nomolotus discontinued social media claims that its herbal supplement supports users’ immune systems during the COVID-19 pandemic and customers reviews referencing the virus after the National Advertising Division questioned the statements as misleading.